Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAd-COV2 Vaccine for COVID-19 Prevention (COVITAR)
NCT04791423Phase 3Completed
- Sponsor
- ReiThera
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Prophylactic Vaccines, Adenoviral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GRAd-COV2 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by ReiThera. Primary endpoints: Number of participants with symptomatic laboratory confirmed COVID-19, Incidence of Adverse Events and 4 more. Started Mar 2021; status: completed.
02
Drugs
GRAd-COV2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04791423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791423.